The Kestrel – it’s made entirely from Hemp

lotus_eco_elise

It’s great that one single plant could solve most of the worlds problems. Hemp has over 50 thousands uses. The problem is no one will let it, because hemp is realy a large threat to corporations that control energy, medicine and a number of other industries.

The Kestrel, hemp based car, was designed in Canada by Calgary-based Motive Industries Inc. And much unlike the United States, the Canadian Government welcomes the idea of hemp farming and actually invests into the industry.

It’s a three-door hatchback that runs on battery power and made from “hemp composite as strong as the fiberglass in boats, yet incredibly lightweight,” Nathan Armstrong, the president of Motive Industries, explained to Popular Science. The composite is made by infusing hemp stalks with polymer resin. It weighs in at not 2,500 pounds and has much better fuel efficiency than other cars and has a very affordable price given the fact that hemp is very easy to grow and requires nothing but the sun. It fits 4 passengers and the production version of it was supposed to be available this year.

Unlike most electric vehicles, the Kestrel relies entirely on electrical power. A 16 kWh lithium-ion battery will allow the Kestrel to go up to 160 km per charge, with a top speed between 90 to 130 km/hr. The Kestrel passed its crash test with flying colors, and upon impact all of its panels bounce right back into shape, much unlike steel!

For thousands of years, 90 percent of all ships rope and sails made from hemp. Hemp is an unlimited, forever lasting resource. For that reason alone it is a threat to our current financial and economic systems. It seems the systems we have in place are used to justify why products like this cannot be mass marketed and mass distributed. It’s time for a change, and it’s time for us to implement new methods and technologies that are more harmonious with the planet.

Medical Marijuana: Where’s the Evidence?

ImageProxy (5)

With many US states now having laws in place to facilitate access to medical marijuana for a variety of medical conditions, two new reviews have highlighted the lack of evidence to support its use in most indications.

An editorial also raises questions about the legal implications for doctors prescribing such products.

The reviews, published in the June 23/30 issue of JAMA, note that 23 states and the District of Columbia have enacted laws to allow prescription of medical marijuana for certain medical conditions.

Reviewing the medical literature on medical marijuana, the two papers come to similar conclusions — that some evidence supports the use of marijuana for nausea and vomiting related to chemotherapy, specific pain syndromes, and spasticity from multiple sclerosis. But for most other indications such as hepatitis C, Crohn’s disease, Parkinson’s disease, or Tourette’s syndrome, they found that the evidence supporting its use is of poor quality.

A third paper in the same issue of JAMA highlights the large variability in specific cannabinoids in various medical marijuana products and finds that contents did not conform to what was advertised on the labelling.

In an accompanying editorial, Deepak Cyril D’Souza, MBBS, and Mohini Ranganathan, MD, Yale University School of Medicine, New Haven, Connecticut, note that for most of the conditions that qualify for medical marijuana use, the evidence fails to meet US Food and Drug Administration (FDA) standards.

They call for government support to conduct high-quality trials. Until such trials are available, they suggest it may be prudent to wait before widely adopting use of marijuana. “Perhaps it is time to place the horse back in front of the cart,” they conclude.

Legal implications Unclear

The editorialists point out that for physicians, the legal implications of certifying patients for medical marijuana remain unclear given the differences between the views of state vs federal government.

They emphasize that the prescription, supply, or sale of marijuana is illegal by federal law, and it is not known to what extent a physician who certifies a patient for medical marijuana may be liable for negative outcomes, and whether malpractice insurance will cover any liability.

In one of the review papers, Kevin P. Hill, MD, McLean Hospital, Belmont, Massachusetts, examined 28 randomized clinical trials of cannabinoids in various indications.

He notes that there are two cannabinoids (dronabinol and nabilone), which are FDA approved for nausea and appetite stimulation.

Apart from these two indications, Dr. Hill found that use of marijuana for chronic pain, neuropathic pain, and spasticity due to multiple sclerosis is supported by high-quality evidence.

Six trials that included 325 patients examined chronic pain, 6 trials that included 396 patients investigated neuropathic pain, and 12 trials that included 1600 patients focused on multiple sclerosis. Several of these trials had positive results, suggesting that marijuana or cannabinoids may be efficacious for these indications.

http://www.medscape.com/viewarticle/847494?nlid=83985_2052&src=wnl_edit_medn_psyc&uac=%%uac%%&spon=12&impID=%%JOBID%%&faf=1

Le cose che nessuno Vi dice – Bedrocan: il farmaco a base di cannabis che sta facendo miracoli contro la sclerosi multipla, ma nessuno ne parla!!!

zzz8

Sapete cos’è il Bedrocan? E’ un farmaco a base di cannabis che sta facendo miracoli, ridà dignità e sollievo ai malati di sclerosi multipla.
Di seguito la testimonianza, giunta a noi attraverso un commento, di una ragazza malata di Sclerosi multipla. Si tratta di uno dei cinque pazienti dell’ospedale di Casarano che stanno sperimentando la somministrazione del Bedrocan, nome medico della Cannabis Terapeutica. “Da quando ho cominciato a usarla, sono rinata”, scrive. Testimoniando il valore che la terapia assume nel miglioramentodella qualità della vita di chi si trova a combattere la difficile battaglia contro la malattia.
Gentile Redazione,
Mi chiamo Lucia,30 anni e vi scrivo dalla provincia di Lecce. Undici anni fa mi fu diagnosticata la Sclerosi Multipla. Vi scrivo in seguito al clamore suscitato dopo i vostri servizi sulla Cannabis Terapeutica che viene somministrata dall’Ospedale Ferrari di Casarano (LE). Al momento sono seguita dal centro SM dello stesso ospedale direttamente dai dottori Sergio Pasca e Roberto De Masi. Io sono una dei 5 “pazienti fortunati” che sta assumendo il Bedrocan (infiorescenze essiccate di Marijuana) con miglioramenti evidenti ed eclatanti nell’andatura,nei tremori,nei dolori,negli spasmi muscolari,nella rigidità,nell’appetito,nell’umore e nel miglioramento totale della qualità di vita.
Sono sempre stata una ragazza attiva,vivace e con la testa sulle spalle,fino a quando non mi è stata diagnosticata questa malattia che ovviamente ha condizionato ogni fase della mia vita. Nei vari anni ho provato tutti i farmaci convenzionali e non che vengono prescritti a coloro che si trovano nella mie condizioni: vari tipi di interferone, antidepressivi, antiepilettici, miorilassanti, immunosoppressori, vitamine, integratori…e chissà quanti altri.. Nel 2008 ho fatto un viaggio ad Amsterdam per testare personalmente le migliori varietà consigliate per la Sclerosi Multipla…ed è lì che ho potuto testare su di me gli effetti benefici della cannabis. A fine maggio di quest’anno,il centro SM dell’Ospedale Ferrari di Casarano,seguito dai dottori Pasca e De Masi,mi ha prescritto la prima ricetta per l’erogazione del farmaco: Bedrocan (a base di infiorescenze).
Prima di arrivare a questo farmaco però il protocollo prevede l’utilizzo di vari altri farmaci (miorilassanti etc.) che anziché calmare i dolori e gli spasmi,su di me non facevano altro che aumentare questi sintomi (per non parlare poi degli effetti collaterali di questi e di tutti gli altri farmaci che ho provato). Come ultima spiaggia, visto che non sto bene con nessun farmaco e visto che la regione Puglia ha approvato la cannabis terapeutica,sono stata ricoverata 6 giorni (come da protocollo) per iniziare questa nuova terapia (seguita sempre e costantemente dai dottori Sergio Pasca e Roberto De Masi).
Sono arrivata in ospedale che ero costretta a star seduta su una sedia a rotelle ormai e mi preparavo all’idea di doverla utilizzare per il resto della mia vita. Dopo 2 giorni di ricovero ho cominciato a bere tisane con la marijuana (somministrate in tre orari diversi della giornata). Il terzo giorno sono resuscitata (per richiamare una citazione delle “Sacre Scritture”). Sono infatti riuscita a lasciare la sedia e iniziare piano piano a camminare nuovamente sulle mie gambe (seppur con un aiuto affianco),avendo così la certezza che tale farmaco è l’unico in grado di sollevare oltre all’umore anche il mio fisico. Sono stata dimessa e mandata a casa con 6 confezioni di Bedrocan sufficienti a trascorre un mese di vita “normale” e ogni mese vado tranquillamente in farmacia (quella dell’Ospedale) a prendere il farmaco (previa ricetta del neurologo).
A questo punto la mia richiesta è semplice. Voglio dare la mia testimonianza di paziente affetta da una malattia gravemente invalidante,trentenne,nel pieno della vita…che ha trovato finalmente un sollievo alle sue sofferenze grazie al Centro SM di Casarano e all’enorme lavoro svolto da tutta l’equipe dei dottori Sergio Pasca e Roberto De Masi. Conosco perfettamente l’iter burocratico che bisogna affrontare affinchè questo farmaco possa giungere ai pazienti che attendono per mesi e mesi,in preda ai dolori e a sofferenze inimmaginabili. Un percorso esageratamente impervio,sia per i malati che per i medici.
Sarebbe fantastico informare tutti coloro che potrebbero usufruire di questo “farmaco” e soprattutto fare in modo che i centri come quello di Casarano abbiano più riflettori puntati addosso in modo da far emergere tutte le ottime attività che vengono svolte quotidianamente in favore dei pazienti affetti da questa e altre serie malattie. Non finirò di ringraziare chi si è impegnato per questa “battaglia”. Ci hanno donato la “libertà di cura”… e scusate se è poco.
Lucia
Fonte : http://www.20centesimi.it/blog/2011/10/28/io-malata-di-sclerosi-rinata-grazie-alla-cannabis-terapeutica/?utm_source=rss&utm_medium=rss&utm_campaign=io-malata-di-sclerosi-rinata-grazie-alla-cannabis-terapeutica
http://jedasupport.altervista.org/blog/cronaca/bedrocan-sclerosi-multipla-guarisce/
Tratto da: http://zapping2015.altervista.org/le-cose-che-nessuno-vi-dice-bedrocan-il-farmaco-a-base-di-cannabis-che-sta-facendo-miracoli-contro-la-sclerosi-multipla-ma-nessuno-ne-parla/

http://iodubito.altervista.org/le-cose-che-nessuno-vi-dice-bedrocan-il-farmaco-a-base-di-cannabis-che-sta-facendo-miracoli-contro-la-sclerosi-multipla-ma-nessuno-ne-parla/

HOW IS CANNABIS REGULATED AT THE STATE LEVEL? MEDICAL OR RECREATIONAL IS THE KEY

 

AAEAAQAAAAAAAAJtAAAAJDRjNDdkMzM5LTRhZjktNDNmMy1hZTU0LTUwOWFkMjA5MThjMA

There is general consensus that the cannabis industry needs to be regulated from a state level, and eventually at a federal level to end the failed “reefer madness” prohibition. Even the medical cannabis industry in California recognizes that the lawlessness of the “wild west” is not sustainable. The question arises who is responsible to implement and enforce a regulatory scheme for overseeing the sale of cannabis on a state level?

So first, let’s turn our attention to the State legislature. In some instances, such as Florida, New York and Georgia, to mention a few, the legality of the use of medical cannabis was approved by the legislature. These type scenarios have firmly left the drafting and implementation of legal cannabis to the state powers.

As you may be aware already, state legislatures are an interesting starting point for cannabis regulation for several reasons. Most state legislatures are bicameral in nature. In other words, there are normally two houses like in the federal system – a lower house of representatives and an upper house of senators.

In terms of achieving consensus regulatory policies, there are jurisdictional battles amongst and within the two houses of the state legislature. There are issues that arise within the delegated committees. Committee chairmen can kill a proposed bill by simple inaction. There are issues that arise along the lines of political party domination. There are issues that arise with the will of the people and the Governor. Even if the Governor is of the same political persuasion as the legislature, there is no guarantee of consensus or approval of implementation and regulation.

Currently, Florida would be a prime example of all of these issues playing out, even after the 2014 voter initiative failed by less than two percentage (2%) points garnering 58% approval of the voting electorate. In Florida, to amend the state constitution, an initiative needs to achieve a super-majority vote of sixty percent (60%) to be deemed successful.

On the other hand, there are states that legalized medical cannabis use by popular vote such as Alaska, California, Michigan, Nevada and Massachusetts. All recreational use has been initiated by voter approval of ballot referendums such as Washington, Oregon, Colorado, Alaska and the District of Columbia.

However, even with voter approval many states are stuck in a holding pattern for actually allowing the legal sale of cannabis for medical purposes. Why?

As previously discussed there are the political reasons for the stalemate. But there is also agency jurisdictional issues that arise as well. Much like in the securities industry context there is always a dispute when the issue of financial regulation takes place since the SEC is ultimately monitored by the Banking and Finance Committee and the CFTC is ultimately monitored by the Agriculture Committee, which for historical purposes focused on futures contracts involving corn, wheat, pork bellies etc. Neither agency wants to cede its perceived jurisdiction, even if doing so might achieve more efficient and streamlined regulation.

In the cannabis industry context, the states have taken a similar approach to regulation as well. If a state has legalized medical cannabis, it is most likely that the state’s Department of Health would be the lead regulator. If there is recreational use permitted, the most likely agency to be involved is the Alcohol or Liquor Control Board. To some extent this makes sense. Medical cannabis involves dosing issues, HIPPA concerns and other medical constraints and mirrors more of the pharmaceutical regulatory framework. Many of these concerns need not be addressed under recreational cannabis use, however public health and safety is always an imbedded concern. Regardless of lead regulator, a state’s Department of Revenue is always involved in the regulatory scheme in order to secure tax revenue that is due to the state based on cannabis sales.

So depending upon whether medical or recreational cannabis use is at issue, the lead regulator will be different and may have a different agenda. Some of those agencies may have “special relationships” with certain vendors or certain lobbyist may be more successful at pressing their clients’ interests than others. It is therefore necessary, to have these state regulatory agencies work with one another, or even create a separate and new regulatory agency, that will try and cohesive and comprehensive draft and implement required regulation. No reasonable person in the cannabis industry wants to see legal product diverted or illegal product placed in the system. The issue of legitimacy is pressing and helps protect against unwanted federal intrusion at the moment which surely involves the DEA.

So it is essential that state regulatory agencies, in conjunction with state legislatures, work together to implement the will of the people by enacting strong legal regulation of the cannabis industry. This will go a long way to legitimizing the shifting paradigm of cannabis production and sale, whether in a medical or regulatory context. However, the only way this can be accomplished is by the state legislatures and respective overseeing agencies to coordinate their efforts on a comprehensive basis, rather than one which simply concentrates on the collection of revenue from cannabis sales

Barry Gainsburg, PA providing legal counsel to the Cannabis and Securities Industry

INSURANCE COMPANIES WARMING UP TO CANNABIS BUSINESSES

insurance-cannabisi-industry

Paul Warshaw, CEO of GreenRush, a California technology company that does business with over fifty medical marijuana dispensaries, says adequate insurance policies for cannabis-based businesses have been “few and far between.”
The landscape is shifting, however, as carriers are taking a fresh look at what is becoming a robust and profitable industry. Insurance underwriters are developing liability coverage that can address the needs of the industry as it expands. Gerry Finley of Munich Reinsurance America states that the policies are likely to come at a premium price.
Adam Weiss and Spencer Uniss, owners of Bolder Cannabis and Extracts in Colorado, say the high prices are due to minimal competition among insurance companies for cannabis-related business coverage. The partners carry a full range of coverage for their multi-tiered business, from workers compensation and health insurance to product liability.

https://www.whaxy.com/news/insurance-for-cannabis-businesses?utm_campaign=Roost&utm_source=Roost&utm_medium=push

Festa della Canapa a Felina

cip

Pubblichiamo il comunicato dell’Associazione Culturale Cannabis Info che annuncia la tradizionale e ormai storica Festa della Canapa di Felina.
_________________________________________________________________________

Approfittiamo per informare i nostri soci e simpatizzanti che da qualche tempo il servizio dei “commenti” del nostro sito è stato inesplicabilmente disattivato, cercheremo di ripristinare il servizio il prima possibile.
Per comunicare con noi: ascia@legalizziamolacanapa.org
________________________________________________________________________

 

felina

Louisiana: Governor Enacts Marijuana Sentencing Reform Measure

images (7)

Republican Gov. Bobby Jindal signed legislation late yesterday significantly reducing criminal penalties for marijuana possession offenses.

House Bill 149, which took effect upon signing, amends the state’s toughest-in-the-nation repeat offender laws for marijuana possession offenses.

Under the previous law, second-time possession offenders faced up to five years of hard labor in prison. Third-time offenders faced up to 20 years hard labor in prison.

Under the revised law, two-time marijuana possession offenders face a maximum sentence of six-months in prison. Three-time offenders face a maximum sentence of two-years in prison. Those convicted of marijuana possession for a fourth time face up to eight years in prison.

First-time offenders found in the possession of 14 grams of cannabis or less now face a maximum penalty of 15 days in jail (reduced from six-months). House Bill 149 allows offenders to apply to have their record expunged if they aren’t convicted of a marijuana violation within two years of the first offense.

According to an analysis by the ACLU, Louisiana ranks #14 in the nation in per-capita marijuana possession arrests.

Gov. Jindal also signed separate legislation, SB 143, amending the state’s dormant Therapeutic Research Act. Specifically, the measure asks the state to adopt rules and regulations “relating to the dispensing of prescribed marijuana for therapeutic use” for patients with glaucoma, spastic quadriplegia, or who are undergoing cancer chemotherapy. However, because this language directly conflicts with federal regulations prohibiting doctors from ‘prescribing’ schedule I controlled substances, it remains to be seen whether any licensed Louisiana physicians will agree to participate in the state’s proposed program.

– See more at: http://blog.norml.org/2015/06/30/louisiana-governor-enacts-marijuana-sentencing-reform-measure/?utm_source=feedburner&utm_medium=email&utm_campaign=Feed%3A+NORMLBlog+%28NORML+Blog%29#sthash.tMClEGi7.dpuf

ADUC – Salute – Notizia – SVIZZERA – Cannabis terapeutica. Riconosciute le sue virtu’

ADUC – Salute – Notizia – SVIZZERA – Cannabis terapeutica. Riconosciute le sue virtu’.

images (6)

La Svizzera riconosce le virtù terapeutiche della cannabis, efficace contro i dolori cronici, legati ad esempio ai tumori o a malattie come la sclerosi multipla. Il consumo di cannabis resta comunque vietato in Svizzera, ricorda l’Ufficio federale di Sanità, che ha finanziato uno studio internazionale sul tema. Ma le autorità elvetiche possono accordare delle autorizzazioni per un limitato utilizzo medico. La cannabis è efficace contro le neuropatie croniche, i dolori conseguenti ai tumori, gli spasmi provocati dalle sclerosi, la nausea dovuta a chemioterapia, la perdita di peso dei malati di aids, i disturbi del sonno e la sindrome di Tourette. Al contrario nessuna evidenza è stata rilevata in merito ai sintomi di ansia. Secondo lo studio, effettuato con 79 test clinici effettuato su oltre 6.000 soggetti, gli effetti collaterali registrati sono quelli di una scarsa salivazione, fatica, nausea, sonnolenza. In conclusione “i risultati di questo studio dimostrano che la cannabis racchiude un potenziale terapeutico nell’insieme promettente”, afferma l’Ufficio federale di Sanità.